FDA Approves New Schizophrenia, Depression Drug Brexpiprazole
the Psychiatry Advisor take:
Clinicians who treat patients with schizophrenia will soon have a new medication in their treatment armamentarium with the FDA’s approval of brexpiprazole (Rexulti), which was developed by pharmaceutical companies Otsuka and Lundbeck.
Brexpiprazole is approved as monotherapy to treat adults with schizophrenia, and as an adjunct treatment in adults with major depressive disorder (MDD). The companies said the new drug will be available to patients early next month.
The drug is an oral medication dosed once daily. For schizophrenia, patients should start with treatment of brexpiprazole with 1 mg once daily, and then titrate up to as much as 4 mg. For MDD, patients should begin with 0.5 mg or 1 mg, and can be titrated to as high as 2 mg.
The approval of brexpiprazole was based on four, placebo-controlled phase III clinical trials (two each for schizophrenia and MDD). In one of the schizophrenia trials, the change in PANSS (Positive and Negative Syndrome Scale) total score from baseline for brexpiprazole at 2 mg/day and 4 mg/day (-20.73 and -19.65, respectively) was greater than that seen with a placebo (-12.01).
“In the clinical trials that led to the FDA’s approval, adding brexpiprazole to ongoing antidepressant therapy helped MDD patients improve unresolved symptoms of MDD.” Michael E. Thase, MD, director of the Mood and Anxiety Program at the University of Pennsylvania School of Medicine, Philadelphia, and a study investigator said in a statement.
Rexulti (brexpiprazole) is approved as a monotherapy in schizophrenia and an adjunct in patients with major depression.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia. Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the U.S. in early August 2015.
The mechanism of action of Rexulti in the treatment of MDD or schizophrenia is unknown. However, the efficacy of Rexulti may be mediated through a combination of partial agonist activity at serotonin 5-HT1 and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. In addition, Rexulti exhibits high affinity (subnanomolar) for these receptors, as well as for noradrenaline alpha1B/2C receptors
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Link Identified Between Cured Meat and Mania in Bipolar Disorder
- Early Risk Factors for Bipolar Disorder Found in Offspring of BD Parents
- First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes
- Daily Drinking Associated With Increased Mortality Risk
- Prevalence of Schizophrenia in Individuals With Type 2 Diabetes
- The Opioid System: The Foundation for Social Risk and Reward
- Correctional Psychiatry: Challenges and Rewards
- Those Left Behind: Working With Suicide-Bereaved Families
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- The Impact of Deafness on Hallucinations and Delusions
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Mental Health Problems in Adolescents With HIV: Overview & Expert Interview
- Should Physicians Play a Role in Minimizing the Societal Cost of Medical Care?
- Digital Cognitive Behavioral Therapy Effective for Individuals With Insomnia
- How Do Medical Scribes Reduce EHR Documentation Burden for Physicians?